Menu

CDC Director Resigns Over Unresolved Conflicts of Interest

Brenda Fitzgerald had drawn criticism for tobacco-related investments, among others.

Jan 31, 2018
Shawna Williams

FLICKR, RAED MANSOURFollowing a report by Politico that she had purchased shares in tobacco, pharmaceutical, and health insurance companies early in her tenure as director of the Centers for Disease Control (CDC), Brenda Fitzgerald resigned from the agency today (January 31). Fitzgerald had previously been criticized by Senator Patty Murray (D-WA) for financial investments that led her to recuse herself from involvement in some aspects of CDC’s work, The Washington Post reports.

See “Trump Administration Chooses New CDC Director

“You don’t buy tobacco stocks when you are the head of the CDC,” Richard Painter, a former chief ethics lawyer for George W. Bush, tells Politico. “It’s ridiculous; it gives a terrible appearance.”

According to a Department of Health and Human Services statement announcing the departure, “Dr. Fitzgerald owns certain complex financial interests that have imposed a broad recusal limiting her ability to complete all of her duties as the CDC Director. Due to the nature of these financial interests, Dr. Fitzgerald could not divest from them in a definitive time period.”

Before assuming the CDC post in July 2017, Fitzgerald had worked as an obstetrician-gynecologist. She had also served as a major in the Air Force and as chief of Georgia’s state health department.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.